Exel cites CABO and zanza progress, aiming for CRC launch readiness
Exel says CABO growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. It flags zanza for immediate CRC launch, citing clinical data and an expanded sales force.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.